🇺🇸 FDA
Pipeline program

Pariglasgene brecaparvovec

DTX401-CL401

Approved small_molecule active

Quick answer

Pariglasgene brecaparvovec for Glycogen storage disease type Ia (GSDIa) is a Approved program (small_molecule) at Lacuna Pharma Pty Ltd with 1 ClinicalTrials.gov record(s).

Program details

Company
Lacuna Pharma Pty Ltd
Indication
Glycogen storage disease type Ia (GSDIa)
Phase
Approved
Modality
small_molecule
Status
active

Clinical trials